Distributor inventory | Tablet
Voglibose 0.3 mg + Metformin hydrochloride 500 mg (sustained/extended release) + Glimepiride 1 mg
Type 2 diabetes mellitus (when diet and exercise alone are not sufficient); helps control high blood sugar, especially post-meal spikes
Glimepiride increases insulin release from the pancreas. Metformin reduces glucose production in the liver and improves insulin sensitivity. Voglibose delays carbohydrate absorption from the gut by inhibiting alpha-glucosidase enzymes, reducing post-meal blood sugar rise.
Oral tablet; take exactly as prescribed. Usually taken with/just before meals (often with breakfast and/or main meals) to reduce stomach upset and control post-meal glucose; swallow whole if sustained/extended release (do not crush/chew). Monitor blood glucose regularly.
Common side effects of VOBIWIN TRIO FORTE 1MG TAB may include:
Risk of hypoglycaemia (higher with missed meals, alcohol, heavy exercise); carry glucose. Metformin may rarely cause lactic acidosis—seek urgent care for rapid breathing, severe weakness, abdominal pain, excessive sleepiness. Use with caution/avoid in severe kidney impairment, severe liver disease, dehydration, severe infection, shock, or heart/respiratory failure; kidney function monitoring required. Stop temporarily before/after iodinated contrast procedures and major surgery as advised. Not for type 1 diabetes or diabetic ketoacidosis. May cause vitamin B12 deficiency with long-term use.
